Pluri Expands Manufacturing Agreement with Remedy Cell, Producing Clinical-Grade Batches
Pluri announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell. Under the ongoing collaboration Remedy Cell's personnel, along with Pluri's Contract Development and Manufacturing Organization division, have successfully completed the full implementation of Remedy Cell's proprietary manufacturing process into Pluri's Good Manufacturing Practice, GMP, facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process robustness and scalability, and manufactured several clinical-grade batches of Remedy Cell's lead candidate. These batches are intended for use in Remedy Cell's initial Phase 1b clinical trial, representing a major step in its clinical development
Trade with 70% Backtested Accuracy
Analyst Views on PLUR
About PLUR
About the author
Pluri Expands Manufacturing Agreement with Remedy Cell to Support Clinical Trials
- Manufacturing Capability Enhancement: Pluri's collaboration with Remedy Cell successfully integrates its proprietary manufacturing process into Pluri's GMP facility, marking the completion of clinical-grade batch production that supports Remedy Cell's initial Phase 1b clinical trial, showcasing the strong synergy in biopharmaceutical development between the two companies.
- Clinical Trial Preparation: The successful manufacture of several clinical-grade batches signifies significant progress for Remedy Cell in its clinical development for treating complex fibrotic diseases, further advancing the clinical application of its secretome-based therapies to meet the urgent market demand for innovative treatment options.
- Expanded Collaboration Scope: PluriCDMO™ will continue to provide additional manufacturing and process development support for Remedy Cell, underscoring their shared commitment to advancing next-generation cell-free biologics that address significant unmet medical needs.
- Successful Technology Implementation: The successful execution of GMP training and engineering runs by Pluri's CDMO division not only enhances the robustness and scalability of the manufacturing process but also solidifies Pluri's position as a trusted partner for complex cell-derived therapies.
Pluri Collaborates with Miss Universe Skincare to Launch Exosome-Enhanced Regenerative Skincare Line
Launch of Cellav: Pluri Inc. has launched Cellav Health and Aesthetics Ltd., a subsidiary focused on developing advanced exosome-based technologies for medical aesthetics using Pluri's proprietary 3D cell expansion platform.
Collaboration with Miss Universe Skincare: Cellav has secured a partnership with Miss Universe Skincare to co-develop a new line of cell-based skincare products, with the first product expected to launch in the first half of 2026.
Market Potential: The beauty market is projected to reach $194.05 billion by 2032, highlighting the significant growth opportunity for Cellav's innovative skincare solutions.
Leadership and Vision: Cellav is led by CEO Katty Dowery, who emphasizes the integration of advanced biotechnology into everyday beauty products, aiming to make regenerative science accessible and impactful.
Plurilock Security Inc. Announces Financial Results for the Second Quarter of Fiscal Year 2025
Financial Performance: Plurilock Security Inc. reported a 159% increase in Critical Services revenue year-over-year and a 42% improvement in Adjusted EBITDA loss for Q2 2025 compared to the same period in 2024.
Revenue Breakdown: Total revenue for Q2 2025 was CAD 16.4 million, with significant contributions from professional services and software sales, while hardware sales decreased as a percentage of total revenue.
Operational Highlights: The company secured new contracts worth CAD 5.9 million across federal and public sector clients and expanded its presence in NATO and other international defense markets.
Future Outlook: Plurilock aims to continue its growth strategy focused on higher-margin offerings and is well-positioned to benefit from increased government spending in cybersecurity and defense sectors.
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
Partnership Announcement: BrainStorm Cell Therapeutics has signed a Letter of Intent with Minaris Advanced Therapies to manufacture its investigational therapy NurOwn® for an upcoming Phase 3b clinical trial, enhancing its manufacturing capabilities in the U.S.
Therapeutic Overview: NurOwn® utilizes autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells aimed at treating neurodegenerative diseases like ALS, and has received Orphan Drug designation from both the FDA and EMA.
Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion
Company Growth and Market Expansion: Pluri Inc. reported a nearly 400% revenue growth in the first nine months of fiscal year 2025, driven by advancements in its CDMO and AgTech businesses, as well as new partnerships in cultivated cacao and coffee markets.
Technological Innovations and Strategic Partnerships: The company is leveraging its proprietary cell expansion technology to produce sustainable food products and has secured additional investments to enhance its operations, while also addressing challenges in healthcare and agriculture sectors.
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
Pluri's Patents and MAIT Cell Therapy: Pluri Inc. has been granted patents for its immune cell expansion technologies, particularly focusing on Mucosal-Associated Invariant T (MAIT) cells, which are promising for treating solid tumors and have the potential to revolutionize cancer immunotherapy.
Innovative 3D Cell Expansion Technology: The company utilizes a proprietary 3D cell expansion technology that mimics the natural environment of immune cells, allowing for efficient large-scale production of MAIT cells, which could lead to "off-the-shelf" therapies for cancer patients.
Pluri Expands Manufacturing Agreement with Remedy Cell to Support Clinical Trials
- Manufacturing Capability Enhancement: Pluri's collaboration with Remedy Cell successfully integrates its proprietary manufacturing process into Pluri's GMP facility, marking the completion of clinical-grade batch production that supports Remedy Cell's initial Phase 1b clinical trial, showcasing the strong synergy in biopharmaceutical development between the two companies.
- Clinical Trial Preparation: The successful manufacture of several clinical-grade batches signifies significant progress for Remedy Cell in its clinical development for treating complex fibrotic diseases, further advancing the clinical application of its secretome-based therapies to meet the urgent market demand for innovative treatment options.
- Expanded Collaboration Scope: PluriCDMO™ will continue to provide additional manufacturing and process development support for Remedy Cell, underscoring their shared commitment to advancing next-generation cell-free biologics that address significant unmet medical needs.
- Successful Technology Implementation: The successful execution of GMP training and engineering runs by Pluri's CDMO division not only enhances the robustness and scalability of the manufacturing process but also solidifies Pluri's position as a trusted partner for complex cell-derived therapies.
Pluri Collaborates with Miss Universe Skincare to Launch Exosome-Enhanced Regenerative Skincare Line
Launch of Cellav: Pluri Inc. has launched Cellav Health and Aesthetics Ltd., a subsidiary focused on developing advanced exosome-based technologies for medical aesthetics using Pluri's proprietary 3D cell expansion platform.
Collaboration with Miss Universe Skincare: Cellav has secured a partnership with Miss Universe Skincare to co-develop a new line of cell-based skincare products, with the first product expected to launch in the first half of 2026.
Market Potential: The beauty market is projected to reach $194.05 billion by 2032, highlighting the significant growth opportunity for Cellav's innovative skincare solutions.
Leadership and Vision: Cellav is led by CEO Katty Dowery, who emphasizes the integration of advanced biotechnology into everyday beauty products, aiming to make regenerative science accessible and impactful.
Plurilock Security Inc. Announces Financial Results for the Second Quarter of Fiscal Year 2025
Financial Performance: Plurilock Security Inc. reported a 159% increase in Critical Services revenue year-over-year and a 42% improvement in Adjusted EBITDA loss for Q2 2025 compared to the same period in 2024.
Revenue Breakdown: Total revenue for Q2 2025 was CAD 16.4 million, with significant contributions from professional services and software sales, while hardware sales decreased as a percentage of total revenue.
Operational Highlights: The company secured new contracts worth CAD 5.9 million across federal and public sector clients and expanded its presence in NATO and other international defense markets.
Future Outlook: Plurilock aims to continue its growth strategy focused on higher-margin offerings and is well-positioned to benefit from increased government spending in cybersecurity and defense sectors.
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
Partnership Announcement: BrainStorm Cell Therapeutics has signed a Letter of Intent with Minaris Advanced Therapies to manufacture its investigational therapy NurOwn® for an upcoming Phase 3b clinical trial, enhancing its manufacturing capabilities in the U.S.
Therapeutic Overview: NurOwn® utilizes autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells aimed at treating neurodegenerative diseases like ALS, and has received Orphan Drug designation from both the FDA and EMA.
Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion
Company Growth and Market Expansion: Pluri Inc. reported a nearly 400% revenue growth in the first nine months of fiscal year 2025, driven by advancements in its CDMO and AgTech businesses, as well as new partnerships in cultivated cacao and coffee markets.
Technological Innovations and Strategic Partnerships: The company is leveraging its proprietary cell expansion technology to produce sustainable food products and has secured additional investments to enhance its operations, while also addressing challenges in healthcare and agriculture sectors.
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
Pluri's Patents and MAIT Cell Therapy: Pluri Inc. has been granted patents for its immune cell expansion technologies, particularly focusing on Mucosal-Associated Invariant T (MAIT) cells, which are promising for treating solid tumors and have the potential to revolutionize cancer immunotherapy.
Innovative 3D Cell Expansion Technology: The company utilizes a proprietary 3D cell expansion technology that mimics the natural environment of immune cells, allowing for efficient large-scale production of MAIT cells, which could lead to "off-the-shelf" therapies for cancer patients.
